ME
MEDP.US Medpace Holdings Inc
- Market cap
- USD 18.3B
- P/E
- 36.3x
- P/B
- 31.27x
- ROE
- 87.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MEDP.US undervalued?
Graham numberThe Graham number of Medpace Holdings Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medpace Holdings Inc fundamental analysis
No fundamental analysis for Medpace Holdings Inc yet.
Medpace Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory…
Full company profileMedpace Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medpace Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 422M | 436M | 705M | 861M | 926M | 1.14B | 1.46B | 1.89B | 2.11B | 2.53B | 2.84B |
| Gross Profit | 172M | 175M | 216M | 246M | 279M | 328M | 432M | 525M | 656M | 761M | 829M |
| Operating Income | 52.5M | 64.9M | 101M | 127M | 167M | 199M | 279M | 337M | 447M | 535M | 605M |
| EBITDA | 99.5M | 111M | 140M | 150M | 187M | 223M | 308M | 362M | 505M | 571M | 639M |
| Net Income | 13.4M | 39.1M | 73.2M | 100M | 145M | 182M | 245M | 283M | 404M | 451M | 510M |
| EPS | 0.37 | 0.98 | 1.98 | 2.67 | 3.86 | 4.82 | 7.29 | 8.88 | 13 | 15 | 18 |
| Balance Sheet | |||||||||||
| Total Assets | 979M | 951M | 968M | 1.14B | 1.39B | 1.66B | 1.35B | 1.66B | 2.10B | 1.98B | 2.30B |
| Total Liabilities | 368M | 447M | 378M | 417M | 585M | 707M | 966M | 1.10B | 1.28B | 1.52B | 1.72B |
| Shareholders' Equity | 611M | 504M | 590M | 726M | 806M | 953M | 386M | 559M | 826M | 459M | 585M |
| Cash & Short-term Investments | 37.1M | 26.5M | 23.3M | 132M | 278M | 461M | 28.3M | 245M | 669M | 497M | 705M |
| Total Debt | 192M | 248M | 192M | 56.2M | 131M | 147M | 208M | 164M | 150M | 137M | 146M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 91.7M | 97.4M | 157M | 202M | 259M | 263M | 388M | 433M | 609M | 713M | 707M |
| Capital Expenditure | 13.5M | 12.3M | 16.0M | 17.9M | 31.3M | 28.3M | 36.9M | 36.6M | 36.5M | 31.4M | 67.8M |
| Free Cash Flow | 78.2M | 85.1M | 141M | 184M | 227M | 235M | 351M | 397M | 572M | 682M | 639M |
| Ratios | |||||||||||
| ROE | 2.2% | 7.8% | 12.4% | 13.8% | 18.0% | 19.1% | 63.5% | 50.6% | 49.0% | 98.3% | 87.2% |
| ROA | 1.4% | 4.1% | 7.6% | 8.8% | 10.5% | 11.0% | 18.1% | 17.1% | 19.2% | 22.8% | 22.2% |
| Net Profit Margin | 3.2% | 9.0% | 10.4% | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% | 18.0% |
| Debt to Equity | 0.31x | 0.49x | 0.33x | 0.08x | 0.16x | 0.15x | 0.54x | 0.29x | 0.18x | 0.30x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medpace Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 11.4M | 0.36 | 4.0% |
| 2022 | USD 22.1M | 0.66 | 9.0% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medpace Holdings Inc
- Insiders 19.07%
- Institutions 80.94%
- Public & others 0.00%
- Shares outstanding 28.0M
- Free float 22.7M
Top funds holding MEDP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 813K | 2.91% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 708K | 2.53% | -2.51% | Sep 2026 |
| Vanguard Small Cap Index | 503K | 1.80% | -4.38% | Sep 2026 |
| Invesco S&P MidCap Quality ETF | 332K | 1.19% | +0.15% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 280K | 1.00% | -7.35% | Sep 2026 |
| Vanguard Explorer Inv | 271K | 0.97% | -8.36% | Sep 2026 |
| iShares Biotechnology ETF | 175K | 0.63% | -0.31% | Oct 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 173K | 0.62% | +271.72% | Jun 2026 |
| T. Rowe Price Lrg Cp Gr I | 170K | 0.61% | -0.60% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 167K | 0.60% | +1.32% | Sep 2026 |
| TD Global Capital Reinvestment - I | 145K | 0.52% | -2.23% | Jun 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 136K | 0.49% | -0.26% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 127K | 0.45% | -0.07% | Oct 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 123K | 0.44% | 0.00% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 107K | 0.38% | +7.62% | Sep 2026 |
| Madison Mid Cap Y | 105K | 0.38% | 0.00% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 104K | 0.37% | +26.67% | Sep 2026 |
| Fidelity Extended Market Index | 104K | 0.37% | -5.60% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 95.7K | 0.34% | -0.06% | Oct 2026 |
| Fidelity Mid Cap Index | 86.7K | 0.31% | -1.20% | Sep 2026 |
Top institutions holding MEDP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.50M | 8.93% | +1.13% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.07M | 7.40% | +614.90% | Jun 2026 |
| AQR Capital Management LLC | 1.28M | 4.57% | -5.53% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.13M | 4.05% | +1.04% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.03M | 3.67% | +1.56% | Jun 2026 |
| State Street Corp | 711K | 2.54% | +4.20% | Jun 2026 |
| Geode Capital Management, LLC | 710K | 2.54% | -4.65% | Jun 2026 |
| Wasatch Advisors LP | 637K | 2.28% | -17.75% | Jun 2026 |
| Amvescap Plc. | 579K | 2.07% | +0.29% | Jun 2026 |
| Renaissance Technologies Corp | 452K | 1.62% | +8.86% | Sep 2026 |
| Baillie Gifford & Co Limited. | 452K | 1.62% | -4.53% | Sep 2026 |
| Arrowstreet Capital Limited Partnership | 429K | 1.53% | +8.40% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 363K | 1.30% | -8.70% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 318K | 1.14% | +10.10% | Jun 2026 |
| UBS Group AG | 304K | 1.09% | -10.72% | Jun 2026 |
| Bessemer Group Inc | 283K | 1.01% | -0.89% | Jun 2026 |
| Mawer Investment Management Ltd | 267K | 0.96% | -40.11% | Jun 2026 |
| TD Global Investment Solutions – TD Epoch | 267K | 0.95% | +89.10% | Jun 2026 |
| TD Asset Management Inc | 264K | 0.94% | +98.32% | Jun 2026 |
| Thrivent Financial For Lutherans | 256K | 0.92% | +10.73% | Jun 2026 |
Medpace Holdings Inc company profile
- Company name
- Medpace Holdings Inc
- Ticker
- MEDP.US
- Exchange
- USA Stocks
- Listed since
- Aug 11, 2016
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 6,600
- Fiscal year end
- December
- Address
- 5375 Medpace Way, Cincinnati, OH, United States, 45227
- Phone
- 513 579 9911
- Website
- medpace.com
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Medpace Holdings Inc management
10- Dr. August James Troendle M.D.CEO, President & Chairman · born 1956
- Mr. Kevin M. BradyCFO & Treasurer · born 1974
- Mr. Stephen P. Ewald J.D.Chief Compliance Officer, General Counsel & Corporate Secretary · born 1969
- Mr. Brad W. HansmanExecutive Vice President of Operations · born 1983
- Chris Carissimi M.B.A.Chief Information Officer
- Ms. Lauren MorrisAssociate Director of Investors Relations
- Mr. Todd MeyersVice President of Business Development & Marketing
- Mr. Weimin Gai MSSenior Vice President of Biometrics
- Mr. John T. Wynne MBAChief Business Officer
- Ms. Reinilde Heyrman M.D.Chief Medical Officer of Medical Department · born 1961